Timothy Noyes

Newleos Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for neuropsychiatric disorders, has appointed Timothy Noyes as President and Chief Executive Officer. 

He succeeds David Donabedian, Ph.D., the company’s Founding President and CEO, who will continue to serve in an advisory capacity.

With more than 30 years of biopharmaceutical leadership experience, Mr. Noyes brings a proven track record of guiding companies through key phases of growth, innovation, and value creation. As CEO, he will oversee the advancement of Newleos’ pipeline of first-in-class and best-in-class therapies targeting generalized anxiety disorder, social anxiety disorder, and substance use disorders.

Mr. Noyes most recently served as CEO of Aerovate Therapeutics, where he successfully led the company’s IPO and progressed its lead clinical program for pulmonary arterial hypertension through a global Phase 2/3 trial. Previously, he was CEO of Proteon Therapeutics, steering the company through its IPO and advancing a novel biologic from pre-clinical to Phase 3 development.

Earlier in his career, he held senior roles at GelTex Pharmaceuticals, overseeing the commercial launch of Renagel for end-stage renal disease, and later served as President of Genzyme’s Renal Division following GelTex’s acquisition. Mr. Noyes began his career at Merck, and holds an A.B. and M.B.A. from Harvard University.

Newleos, which launched in 2025 with a $93.5 million Series A financing, is backed by Goldman Sachs Alternatives, Novo Holdings, Longwood Fund, DCVC Bio, and Arkin Bio Capital.